Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & DohmefiledCriticalSchering Corp
Priority to DO2003000676ApriorityCriticalpatent/DOP2003000676A/en
Publication of DOP2003000676ApublicationCriticalpatent/DOP2003000676A/en
La presente invención proporciona una composición fannaceutica que comprende un inhibidor de la absorción de colesterol y un inhibidor de una HMGCoA reductasa, uno o mas antioxidantes, celulosa microcristalina, hidroxipropil metilcelulosa, estearato de magnesio y lactosa. La composición no necesita contener acido ascórbico en orden de obtenerla estabilidad deseable.The present invention provides a fanatic composition comprising a cholesterol absorption inhibitor and an HMGCoA reductase inhibitor, one or more antioxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition does not need to contain ascorbic acid in order to obtain desirable stability.
COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
Compounds derived from substituted pyrrolidines, inhibitors of factor xa and / or inhibitors on serine protease; pharmaceutical composition comprising said compounds; procedure to prepare the pharmaceutical composition; and use of the compounds to prepare a medicamneto with an antithrombotic effect